|
|
Comparison of Effect, Recurrence, Metastasis and Adverse Reactions of TS and SOX in Postoperative Adjuvant Chemotherapy for Gastric Cancer |
QIN Hai-yun, LI Feng-zhen, WANG Ning,et al |
Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110034 |
|
|
Abstract 【Objective】To compare the effect of TS and SOX in postoperative adjuvant chemotherapy of gastric cancer. 【Methods】A total of 96 patients with postoperative adjuvant chemotherapy for gastric cancer were randomly divided into two groups. There were 49 patients in the observation group who were treated with SOX (Oxaliplatin + Teggio capsule), while 47 patients in the control group were treated with the TS regimen (paclitaxel liposome + tigeo capsule). The treatment course in both groups lasted for 5 cycles. The clinical efficacy, recurrence, and adverse reactions of the two groups were compared during the postoperative adjuvant chemotherapy with 3-year follow-up. 【Results】The total effective rate of the observation group was higher than that of the control group (59.2% vs 36.2%, P<0.05); The clinical benefit rate of the observation group was higher than that of the control group (83.7% vs 63.8%, P<0.05). The overall improvement rate of life quality in the observation group was higher than that of the control group (55.1% vs 31.9%, P<0.05). CEA and AFP of two groups showed no differences before and after treatment (P>0.05). The levels of CA199, CA125 and NSE in the observation group were significantly decreased after treatment ( P<0.05), while those tumor markers in the observation group were significantly lower than those in the control group ( P<0.05). The incidence rate of marrow suppression and liver function damage between the two groups did not show significant difference (P>0.05), while the incidence rate of nausea, vomiting, diarrhea and pain in the observation group were significantly lower than those in the control group (P<0.05). The RSF and OS in the observation group were significantly higher than those in the control group within 3 years (P<0.05); The peritoneal metastasis of the observation group was significantly lower than that of the control group (P<0.05). 【Conclusion】 Compared to TS chemotherapy, SOX chemotherapy has better clinical effects in adjuvant chemotherapy for gastric cancer with lower recurrence and metastasis rates and less incidence of adverse reactions.
|
Received: 20 November 2018
|
|
|
|
|
[1] 彭东旭, 方晓娟, 杜均详,等. 奥沙利铂联合替吉奥或紫杉醇脂质体化疗方案一线治疗晚期胃癌的疗效比较[J]. 中国肿瘤临床与康复, 2016,23(6):686-688. [2] 王继贤.紫杉醇脂联合顺铂与替吉奥联合顺铂在晚期非小细胞肺癌患者中的应用效果对比[J]. 癌症进展, 2016, 14(3):272-273. [3] Hirotoshi I, Masashi I, Hironori F, et al. Comparison of the control of nausea and vomiting among several moderately emetic-risk chemotherapy regimens[J]. Cancer, 2016, 7(5):569-575. [4] 熊天增.紫杉醇脂质体联合奥沙利铂及替吉奥治疗晚期胃癌的疗效和安全性分析[J]. 四川医学, 2016,37(10):1171-1174. [5] 杨学宁, 吴一龙. 实体瘤治疗疗效评价标准—RECIST[J]. 循证医学, 2004, 4(2):85-90. [6] 黎超. SOX方案一线化疗后替吉奥维持治疗晚期胃癌的临床观察[J]. 实用肿瘤杂志, 2017, 32(6):520-524. [7] 黄向东, 牛强, 郭伟. 奥沙利铂联合紫杉醇脂质体和替吉奥治疗晚期胃癌的临床疗效及可行性研究[J]. 中国药物与临床, 2017,17(3):375-377. [8] 赵运成, 刘和平, 王桂琦. 替吉奥联合奥沙利铂新辅助化疗治疗胃癌疗效观察[J]. 现代中西医结合杂志, 2016, 25(9):991-993. |
[1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(3): 601-603. |
|
|
|
|